Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, announced that Denis Johnson has joined the company as Chief Operating Officer (COO). Denis joins Kindeva to lead global operations for all of Kindeva’s state-of-the-art manufacturing, research and development sites located in the United States and United Kingdom .
As COO, he will focus on global operations, including facilitating the expansion and opening of Kindeva’s new injectable aseptic fill and finish facility in Bridgeton, Mo. , scheduled to open this year, as well as the company’s focus on introducing green propellant gases into the more environmentally friendly commercial manufacturing of combination products for inhalers, with Kindeva being the only CDMO capable of filling inhalers with a gas low global warming potential (GWP) 152a thruster. Denis has extensive leadership and manufacturing experience in the life sciences field that he brings to this role. Most recently, he was responsible for global manufacturing and technical operations at Biogen and held several leadership positions at Catalent, Boston Scientific, Teradyne and Johnson & Johnson. He began his career in the United States Army managing logistics and operations.
“ Denis’ extensive CDMO experience and track record of operational excellence will be invaluable as Kindeva continues to grow and innovate in the drug delivery space,” said Milton Boyer , CEO of Kindeva. Kindeva. “ His strong leadership skills and deep understanding of the market will help Kindeva introduce the first commercial line of Green Propellant 152a to the market: clinical supply is already available and by 2025 we plan to introduce some of the very first products using this alternative propellant on the market. Additionally, Denis will focus on optimizing manufacturing processes, maximizing operational efficiency, ensuring excellence in quality and compliance across all sites, etc.
Also Read: Red Hat Expands Red Hat Trusted Software Supply Chain for a Developer-First Experience
“ Kindeva’s commitment to more sustainable, patient-focused drug delivery systems and its continued growth, particularly over the past year, is truly exciting,” said Mr. Denis. “ I am very excited to join the Kindeva team so that we can pursue operational excellence and implement strategies that ensure the timely delivery of life-changing medicines to patients around the world.”
SOURCE: BusinessWire